American Cancer Society Guideline for Prostate Cancer Early Detection

Prostate cancer screening can lower your risk of developing advanced prostate cancer and of dying from prostate cancer. The goal of screening is to find prostate cancers that are likely to grow quickly and be life threatening, while avoiding unneeded tests and treatments for prostate cancers that are unlikely to cause harm.

The American Cancer Society (ACS) recommends screening for prostate cancer with the prostate-specific antigen (PSA) blood test.

For men at average risk of prostate cancer

Most men don’t fall into the higher-risk categories below. Men at average risk should be screened with a PSA test every 2 years from ages 50 through 69 years.

For men at higher risk of prostate cancer

Black men should begin screening at age 45 and get a PSA test every year through age 69.

Non-Black men with a family history of prostate cancer in a close relative (father, brother, or son) should begin at age 45 and get screened through age 69:

  • Get screened every year if a close relative was diagnosed with prostate cancer before age 65, or if more than 1 of these relatives has had prostate cancer.
  • Get screened every 2 years if only 1 close relative was diagnosed with prostate cancer and it was at age 65 or older.

Some men might have an inherited gene change, such as a mutation in the BRCA2 gene, that increases their risk. If you have an inherited condition that increases your risk of prostate cancer, or if you have a close relative with a gene mutation linked with higher risk and you haven’t been tested for it yourself, talk with your healthcare provider about when screening should begin and how often it should be done.

For all men

At ages 70 to 74, it’s not as clear whether the benefits of prostate cancer screening outweigh the risks and possible harms. Men in this age range should discuss with their healthcare provider whether continuing screening is right for them. If you choose to get screened, it should be every 2 years.

At ages 75 and older, ACS does not recommend screening.

  • Some men ages 75 to 79 who are very healthy may want to continue screening, especially if their PSA has been rising on previous tests. But this should be discussed with your healthcare provider.
  • Screening is discouraged after age 80 under all circumstances.

Screening is also not recommended at any age if you are in poor health and not expected to live at least another 10 years.

ACS does not recommend the digital rectal exam (DRE) as a screening test for prostate cancer. However, this exam might be done as part of your workup if you might have prostate cancer; for example, if your PSA level is high.

Informed decision making

Before you start screening, your healthcare provider should make sure you are informed about:

If your PSA is high (abnormal)

Your PSA is considered high if:

  • It is 3 ng/mL or higher, and you are younger than 70
  • It is 6.5 ng/mL or higher, and you are 70 or older

If your PSA is high, the test should be repeated to confirm this, preferably 2 weeks to 3 months later.

If your PSA is still high, most men should get further testing with a prostate MRI and/or a biomarker test to help determine their risk of having prostate cancer and whether they should get a prostate biopsy. For some men where the suspicion of cancer is high, such as those with a very high PSA, your doctor might suggest going straight to a biopsy.

Having a high PSA does not necessarily mean that you have prostate cancer, and it does not mean that you automatically need a prostate biopsy. Some of the possible harms of screening can be reduced by repeating the PSA test to ensure it’s accurate and, if the PSA is still high, by doing other tests, such as a prostate MRI and/or biomarker test, to help determine whether a biopsy is needed.

Active surveillance for low-risk prostate cancer

If you are diagnosed with prostate cancer that has a low risk of growing or spreading, your doctor should offer active surveillance as the initial management option.

Active surveillance means closely monitoring the cancer, including regular biopsies, PSA testing, and possibly MRIs. Treatment would then be recommended if there are signs that the cancer is becoming higher risk. Active surveillance can help some men avoid or delay urinary, sexual, and bowel problems that could be caused by prostate cancer treatment, while still allowing the cancer to be treated effectively if treatment does become necessary. Active surveillance has been shown to be a sensible and safe approach for men with low-risk prostate cancer.

side by side logos for American Cancer Society and American Society of Clinical Oncology

Developed by the American Cancer Society medical and editorial content team with medical review and contribution by the American Society of Clinical Oncology (ASCO).

Hoffman RM, Wolf AMD, Etzioni R, et al. American Cancer Society guideline for the early detection of prostate cancer, 2026. CA Cancer J Clin. 2026; e70112. doi:10.3322/caac.70112.

Smith RA, Andrews KS, Brooks D, et al. Cancer screening in the United States, 2019: A review of current American Cancer Society guidelines and current issues in cancer screening. CA Cancer J Clin. 2019;69(3):184-210.

Last Revised: November 12, 2026

American Cancer Society Emails

Sign up to stay up-to-date with news, valuable information, and ways to get involved with the American Cancer Society.